Table 1.
Baseline characteristics of patients by allocation
| Demographics and disease characteristics | No intervention | Podiatry |
| N | 18 | 16 |
| Female: n (%) | 13 (72%) | 12 (75%) |
| Age: years (SD) | 64.6 (12.1) | 56.8 (10.2) |
| Disease duration: years (SD) | 16.7 (10.1) | 14.1 (11.9) |
| DAS (0–10): median score (IQR) | 4.3 (3.5,5.2) | 3.7 (3.1,4.2) |
| HAQ score (0–3): median score (IQR) | 1.04 (0.48,1.71) | 0.75 (0.63,1.13) |
| BMI: median score (IQR) | 27.0 (22.6,32.3) | 27.0 (24.8,30.5) |
| Pharmacological management | ||
| Analgesics: n (%) | 8 (44%) | 6 (38%) |
| NSAIDs: n (%) | 9 (50%) | 8 (50%) |
| DMARDs: n (%) | 12 (67%) | 14 (88%) |
| Biologic agent: n (%) | 2 (11%) | 1 (6%) |
| Corticosteroid: n (%) | 5 (28%) | 4 (25%) |
| Other: n (%) | 2 (11%) | 2 (13%) |
| Foot disease | ||
| LFISIF (0–21): median score (IQR) | 13 (12,14) | 15 (12,16) |
| LFISAP (0–30) median score (IQR) | 21 (16,26) | 17 (15,24) |
| Function | ||
| Walking speed (m/s): median score (IQR) | 0.70 (0.40,1.09) | 0.88 (0.76,1.00) |
DAS, Disease Activity Score; HAQ, Health Assessment Questionnaire; BMI, Body Mass Index; NSAIDs, Non-Steroidal Anti Inflammatory Drugs; DMARDs, Disease Modifying Anti-Rheumatic Drugs, LFIS, Leeds Foot Impairment Score (IF, Impairment/footwear subscale, AP, Activity limitation/participation restriction subscale). Values are presented as mean (standard deviation) or median (inter-quartile range).